TELA — Tela Bio Inc
NASDAQ · Healthcare · Medical Devices
$0.79
+$0.05 (+7.22%)
Tela Bio Inc (TELA) is a medical devices company listed on NASDAQ. It is led by Roberto E. Cuca J.D., based in 1 Great Valley Parkway, Malvern, PA, United States, 19355, with about 218 employees. TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest reported TELA revenue for 2025-09-30 was $20.7M. Net income was -$29.8M. Revenue was up 2.4% from 2025-06-30 to 2025-09-30. TELA currently screens at market cap $38.5M.
Use this TELA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TELA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TELA SEC filings page. Lician reads the product cache first so this HTML stays unique to Tela Bio Inc even when a live quote feed is slow.
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Key Statistics
Market Cap
$38.46M
Volume
61,970
Previous Close
$0.70
Day Range
$0.65 – $0.70
P/B Ratio
7.30
EPS
-$1.33
Revenue
$69.30M
Net Income
-$37.84M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+18.6%
Profit Margin
-54.6%
Employees
218
TELA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $69.30M | $58.45M | $41.42M | $29.46M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$37.84M | -$46.66M | -$44.30M | -$33.28M |
| EPS (Diluted) | -$1.33 | -$2.04 | -$2.72 | -$2.30 |
Total Assets
$86.57M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$52.67M
Operating Cash Flow
-$41.59M
Free Cash Flow
$0.00
Tela Bio Inc Company Information
- CFO, Corporate Secretary & COO
- Roberto E. Cuca J.D.
- Headquarters
- 1 Great Valley Parkway, Malvern, PA, United States, 19355
- Website
- www.telabio.com
- Phone
- 484 320 2930
- IPO / Founded
- 2019-11-08
- Sector
- Healthcare
- Industry
- Medical Devices